Navas, FranciscoChocarro Calvo, AnaIglesias Hernández, PatriciaFernández García, PalomaMorales, VictoriaGarcía Martínez, José ManuelSanz, RaúlDe la Vieja, AntonioGarcía Jiménez, CustodiaGarcía Muñoz, Rafael Á.2024-05-212024-05-212024-04-09 Francisco Navas, Ana Chocarro-Calvo, Patricia Iglesias-Hernández, Paloma Fernández-García, Victoria Morales, José Manuel García-Martínez, Raúl Sanz, Antonio De la Vieja, Custodia García-Jiménez, Rafael A. García Muñoz. Journal of Medicinal Chemistry, 2024, 67, 6410-6424.0022-2623https://hdl.handle.net/10115/33019Este artículo describe la síntesis y caracterización de dos compuestos de Pt(IV) como profármacos antitumorales que incorporan ligandos bis-organosilano en las posiciones axiales. Estos compuestos han sido testado en células cancerosas de colon y células intestinales sanas, aportando resultados muy prometedores en términos de actividad citotóxica. La gran actividad de uno de ellos se ha permitido analizar su comportamiento en ratones con tumores de colon.We report two novel prodrug Pt(IV) complexes with bis-organosilane ligands in axial positions: cis-dichloro(diamine)-trans-[3-(triethoxysilyl)propylcarbamate]- platinum(IV) (Pt(IV)-biSi-1) and cis-dichloro(diisopropylamine)-trans-[3-(triethoxysilyl) propyl carbamate]platinum(IV) (Pt(IV)-biSi-2). Pt(IV)-biSi-2 demonstrated enhanced in vitro cytotoxicity against colon cancer cells (HCT 116 and HT-29) compared with cisplatin and Pt(IV)-biSi-1. Notably, Pt(IV)-biSi-2 exhibited higher cytotoxicity toward cancer cells and lower toxicity on nontumorigenic intestinal cells (HIEC6). In preclinical mouse models of colorectal cancer, Pt(IV)-biSi-2 outperformed cisplatin in reducing tumor growth at lower concentrations, with reduced side effects. Mechanistically, Pt(IV)- biSi-2 induced permanent DNA damage independent of p53 levels. DNA damage such as double-strand breaks marked by histone gH2Ax was permanent after treatment with Pt(IV)-biSi-2, in contrast to cisplatin's transient effects. Pt(IV)-biSi-2's faster reduction to Pt(II) species upon exposure to biological reductants supports its superior biological response. These findings unveil a novel strategy for designing Pt(IV) anticancer prodrugs with enhanced activity and specificity, offering therapeutic opportunities beyond conventional Pt drugs.engAttribution 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/article10.1021/acs.jmedchem.3c02393info:eu-repo/semantics/openAccess